SimpleScreen CRC's 18.2% Precancerous Sensitivity Exposes the Gap Between Regulatory Approval and Population Screening Impact

Freenome's Updated Colorectal Cancer Test Shows Improved Efficacy

Freenome's updated blood-based colorectal cancer screening test, SimpleScreen CRC, met its primary and secondary endpoints in a pivotal validation study, demonstrating improved sensitivity over its first-generation version, particularly for precancerous lesions. The new test achieved 80.4% sensitivity for colorectal cancer and 18.2% for advanced precancerous lesions, compared to 79.2% and 12.5% respectively for the earlier version. Abbott, which has a collaboration agreement with Freenome, is set to commercialize the test upon FDA approval, positioning it as a dominant player in the colorectal cancer screening market. Freenome expects FDA review for its first-generation test by mid-2026 and plans a supplemental PMA for the updated version. A $70 million milestone payment is tied to the next-generation test's FDA approval and technology transfer.

• Freenome's updated SimpleScreen CRC blood test demonstrated significant improvements in detecting colorectal cancer and advanced precancerous lesions. The test achieved 80.4% sensitivity for colorectal cancer and 18.2% for advanced precancerous lesions, surpassing the first-generation test's 79.2% and 12.5% sensitivities, respectively. This enhanced performance brings the test closer to matching the efficacy of certain stool-based screening methods.
• Abbott, a major player in diagnostics, is set to commercialize Freenome's SimpleScreen CRC test following FDA approval, based on a collaboration agreement signed in August 2025. This partnership is expected to establish Abbott as a dominant force in the colorectal cancer screening market, leveraging its existing presence with the Cologuard stool-based test. A $70 million milestone payment is contingent upon the next-generation test's FDA approval and successful technology transfer.
• Freenome has already submitted a premarket approval (PMA) application for its first-generation test, with an FDA review expected by mid-2026. The company plans to submit a supplemental PMA for the improved next-generation SimpleScreen test. This strategic regulatory approach, combined with the test's non-invasive nature, aims to expand screening access for individuals hesitant about traditional methods like stool tests or colonoscopies, competing with existing blood tests like Guardant Health's Shield.

Why Blood-Based Colorectal Cancer Screening is a Critical Unmet Need

Colorectal cancer (CRC) screening uptake remains persistently inadequate across a broad range of populations, with structural, financial, cultural, and logistical barriers collectively driving disparities in early detection. Recent literature from 2023–2026 highlights several high-priority underserved groups where targeted intervention is urgently needed. Addressing these gaps is foundational to improving CRC outcomes at a population level.

• Adults aged 45–49 years represent a critically under-screened cohort following guideline expansion. Despite adherence improving from 20% in 2021 to 46% in 2023, this age group continues to demonstrate significantly lower screening likelihood compared to adults aged 50–75 years (2023 aPR=0.59, 95% CI=0.56–0.62), indicating that awareness and system-level uptake have not yet normalized for this newly eligible population.

• Federally Qualified Health Center (FQHC) populations face substantial and well-documented screening gaps relative to the general U.S. population, despite FQHCs serving nearly 30 million people nationwide. A study of 264,465 FQHC patients found overall mt-sDNA adherence of 55.9%, with adherence further reduced by uninsured status, higher social vulnerability scores, and residence in lower-income ZIP codes. Persistent nonfinancial barriers — including transportation, scheduling difficulties, and language access — continue to limit screening completion even where out-of-pocket costs have been eliminated.

• Racial and ethnic minority groups — including non-Hispanic Asian Americans, American Indian/Alaska Native (AI/AN) communities, and recent immigrant populations — carry a disproportionate screening burden. Non-Hispanic Asian Americans showed significantly lower screening odds (OR: 0.55, 95% CI: 0.42–0.72) compared to non-Hispanic Whites. AI/AN populations have experienced the largest increase in early-onset CRC incidence, the second highest overall CRC incidence rates nationally, and the Alaska Native community carries the highest CRC rates worldwide. Foreign citizenship was independently associated with excess non-participation in CRC screening programs in Italy, underscoring the cross-national nature of immigrant screening disparities.

• Low-income Asian American communities (specifically Chinese, Korean, and Vietnamese adults) served by FQHCs face compounding inner- and outer-context barriers, including lack of language-concordant providers, high staff turnover, referral wait times, transportation challenges, and cultural stigma. Community-clinic-academic partnerships — such as the Advancing Care Together (ACCT) network in Orange County, California — have demonstrated value in deploying culturally and linguistically aligned evidence-based strategies to address these multilevel barriers.

• Low- and middle-income countries (LMICs) and resource-limited settings represent a major global unmet need, where high cost and limited availability of existing screening modalities severely restrict adoption. In sub-Saharan Africa, across 11 urban cancer registries in nine countries, only 58.6% of cancer patients received chemotherapy, with 13.2% recommended but not receiving treatment. Barriers spanned accessibility (transport costs), affordability (treatment costs, work absence), and acceptability (knowledge gaps, fear of treatment), with severity varying significantly by country and national Human Development Index.

• Previous non-responders to organized screening programs represent a sizeable and underaddressed pool. In a Florence-based randomized trial of 20,225 non-respondents, standard re-invitation achieved only 5.7% participation. Behavioral economics-inspired feedback messages increased participation to 7.4% (OR=1.32, 95% CI: 1.10–1.57), while more invasive alternative modalities such as sigmoidoscopy reduced participation. This underscores the importance of low-burden, behaviorally informed outreach strategies for re-engagement.

• Patients without regular healthcare contact — those lacking periodical hospital visits for comorbidities — are disproportionately diagnosed symptomatically rather than through screening. In a Japanese registry study, over 70% of CRC cases were diagnosed outside of screening, with only 23.9% of the symptomatic group diagnosed at an early stage compared to 57.3% in a structured follow-up group, highlighting a critical detection gap in populations outside routine care pathways.

SimpleScreen CRC's Pivotal Study: Improved Sensitivity for Early Detection

The NordICC Trial (NCT00883792), a multicountry, population-based randomised controlled trial enrolling 84,583 men and women aged 55–64 years across Norway, Poland, and Sweden, evaluated a one-time colonoscopy screening versus no screening over a 13-year follow-up period. At 13 years, colorectal cancer incidence was 1.46% in the screening group versus 1.80% in the no-screening group (RR 0.81, 95% CI 0.71–0.90 in intention-to-screen analyses; RR 0.55, 95% CI 0.33–0.81 per-protocol). Notably, the benefit was more pronounced for distal colorectal cancer (RR 0.79, 95% CI 0.65–0.89) than proximal disease (RR 0.91, 95% CI 0.71–1.09), and greater in men (RR 0.77) than women (RR 0.87). Colorectal cancer mortality was numerically lower in the screening arm (0.41% vs. 0.47%), but the difference did not reach statistical significance (RR 0.88, 95% CI 0.68–1.08 by intention-to-screen), with the observed mortality in the non-screening group substantially lower than the 0.82% projected at trial design.

The UCLA Health Randomised Clinical Trial (NCT05275530, 2025) examined four outreach strategies in 20,509 primary care patients aged 45–49 years: FIT-only active choice, colonoscopy-only active choice, dual-modality (FIT or colonoscopy) active choice, and usual care default mailed FIT outreach. At six months, overall screening participation was 18.6%. The usual care default mailed FIT arm achieved the highest participation at 26.2%, significantly outperforming all active choice arms (FIT-only: 16.4%, rate difference −9.8%; colonoscopy-only: 14.5%, rate difference −11.7%; dual-modality: 17.4%, rate difference −8.9%; all P<0.001). Within the dual-modality arm, colonoscopy uptake substantially exceeded FIT uptake (12.0% vs. 5.6%, rate difference −6.4%, P<0.001), and offering dual modality yielded modestly higher participation than single-modality active choice (17.4% vs. 15.4%, rate difference −1.8%, P=0.004). Safety outcomes were not explicitly reported in this study.

The China Cancer Screening Program (2020–2023), conducted across 358 primary healthcare units and targeting residents aged 45–74 years, stratified participants into FIT-positive and FIT-negative (but high-risk factor questionnaire-positive) groups. Participation rates were 32.62% in the FIT-positive group versus 17.11% in the FIT-negative group. Across both groups, 44 CRC cases, 601 advanced adenomas, and 1,789 non-advanced adenomas were detected, with positive predictive values uniformly greater in the FIT-positive group. Among FIT-positive individuals, 40% of CRC cases were detected at Stage I, compared with only 15% in the FIT-negative group. Detection costs per CRC case were approximately $22,196, with FIT-positive group costs reduced by nearly 80% relative to the FIT-negative group for CRC detection and by more than 50% for advanced and non-advanced neoplasms. A risk stratification model combining FIT results with clinical risk factors demonstrated superior performance over models using either parameter alone, underscoring the value of integrated screening approaches.

SimpleScreen CRC's Position in the Evolving Screening Landscape

Comparative data across investigational and standard-of-care CRC screening modalities reveals a rapidly evolving landscape, with emerging technologies showing variable performance relative to established approaches. While colonoscopy remains the procedural benchmark, newer blood-based assays, AI-driven diagnostics, and technical colonoscopy refinements are being evaluated against it — with cost-effectiveness, sensitivity, and real-world compliance all serving as critical differentiators.

Freenome's SimpleScreen CRC: A New Era for Early Detection

The latest validation study for Freenome's SimpleScreen CRC test represents a pivotal moment in the fight against colorectal cancer (CRC). With CRC ranking as the second leading cause of cancer-related deaths globally and a concerning rise in rates among younger populations, the need for more effective and accessible screening methods is paramount. Current screening options, while valuable, often face challenges with patient adherence. Blood-based tests, leveraging advanced techniques and artificial intelligence, are emerging as a promising solution to address these gaps.

Freenome's updated test, demonstrating improved sensitivity for both CRC and, critically, for advanced precancerous lesions, offers a significant step forward. This enhanced ability to detect early-stage disease and pre-cancerous indicators could lead to earlier interventions and ultimately reduce CRC incidence and mortality. The strategic collaboration with Abbott, a diagnostics powerhouse, provides a robust commercialization pathway, leveraging Abbott's extensive market reach and experience in bringing diagnostic innovations to patients.

However, the path to widespread adoption is not without its hurdles. Key considerations include:

• Regulatory Timelines: The multi-stage FDA approval process, with the first-generation test expected by mid-2026 and the updated version requiring a supplemental PMA, means that market entry for the most advanced version could be several years away.

• Competitive Landscape: The market for CRC screening is dynamic, with other blood-based tests and established methods vying for market share. Demonstrating superior clinical utility and cost-effectiveness will be crucial for Freenome and Abbott.

• Specificity and Healthcare Burden: While sensitivity is a highlight, the test's specificity will be critical. High false positive rates could overwhelm colonoscopy capacity, increasing costs and patient anxiety. Medicare's criteria for blood-based tests, including a specificity of at least 90%, underscore this importance.

Ultimately, the success of SimpleScreen CRC will hinge on its ability to navigate these challenges, secure broad payer coverage, and integrate seamlessly into existing screening paradigms, offering a compelling option that improves patient adherence and outcomes.